ProCE Banner Activity

Advanced Renal Cell Carcinoma: Experts Answer Your Questions

Clinical Thought

In this commentary, experts answer questions on managing patients with advanced renal cell carcinoma asked by the audience during a live webinar in June 2023.

Released: July 14, 2023

Share

Faculty

Eric Jonasch

Eric Jonasch, MD

Professor, Department of GU Medical Oncology
UT MD Anderson Cancer Center 
Houston, Texas

Brian Rini

Brian Rini, MD, FASCO

Chief of Clinical Trials 
Division of Hematology/Oncology 
Vanderbilt University Medical Center
Nashville, Tennesee 

Tian Zhang

Tian Zhang, MD, MHS

Associate Professor
Genitourinary Oncology and Multi-Disease Precision Oncology Programs
Division of Hematology and Oncology
Department of Internal Medicine
UT Southwestern Medical Center
Harold C. Simmons Comprehensive Cancer Center
Dallas, Texas

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb

Program Director Disclosure

Program Director

Eric Jonasch, MD

Professor, Department of GU Medical Oncology
UT MD Anderson Cancer Center 
Houston, Texas

Eric Jonasch, MD: consultant/advisor/speaker: Aveo, Aravive, Calithera, DAVA Oncology, Eisai, Exelixis, Genentech, Ipsen, Merck, NiKang, Takeda; researcher: Arrowhead, Merck, NiKang.

Faculty Disclosure

Primary Author

Brian Rini, MD, FASCO

Chief of Clinical Trials 
Division of Hematology/Oncology 
Vanderbilt University Medical Center
Nashville, Tennesee 

Brian Rini, MD, FASCO: consultant/advisor/speaker: Alkermes, Aravive, Arrowhead, Athenex, Aveo, Bristol-Myers Squibb, Corvus, Debiopharm, Eisai, EUSA, GNE/Roche, HiberCell, Merck, Nikang Therapeutics, Pfizer, Surface Oncology, Synthorx; researcher (paid to institution): ADC Therapeutics, Adela, Aravive, Arcus, Arrowhead, Astra-Zeneca, AVEO, Bristol-Myers Squibb, Daiichi Sankyo, Dracen, Dragonfly, Exelixis, Genentech, Gilead, HiberCell, Incyte, Janssen, Merck, Pfizer, Pionyr, POINT Biopharma, Stata Oncology, Surface Oncology, Tempus, VasGene; individual publicly traded stocks and stock options: PTC Therapeutics.

Tian Zhang, MD, MHS

Associate Professor
Genitourinary Oncology and Multi-Disease Precision Oncology Programs
Division of Hematology and Oncology
Department of Internal Medicine
UT Southwestern Medical Center
Harold C. Simmons Comprehensive Cancer Center
Dallas, Texas

Tian Zhang, MD, MS: consultant/advisor/speaker: Amgen, AstraZeneca, Aveo, Bayer, Bristol-Myers Squibb, Calithera, Dendreon, Eisai, Exelixis, Janssen, Lilly, Merck, Pfizer, PlatformQ, QED Therapeutics, Sanofi-Aventis, Seagen, Vaniam Group; researcher (paid to institution): AbbVie/StemCentrx, AstraZeneca, Janssen, Lilly, Merck, Merrimack, Mirati Therapeutics, Novartis, Pfizer, Regeneron, Tempus; Data Safety Monitoring Board: Aravive.